MYT1L
Basic information
Region (hg38): 2:1789113-2331664
Links
Phenotypes
GenCC
Source:
- intellectual disability, autosomal dominant 39 (Strong), mode of inheritance: AD
- intellectual disability, autosomal dominant 39 (Strong), mode of inheritance: AD
- syndromic intellectual disability (Supportive), mode of inheritance: AD
- intellectual disability, autosomal dominant 39 (Strong), mode of inheritance: AD
- syndromic intellectual disability (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Intellectual developmental disorder, autosomal dominant 39 | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Neurologic | 21990140; 23033978; 23160955; 25232846; 26240977; 30055078 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (18 variants)
- Intellectual disability, autosomal dominant 39 (14 variants)
- Intellectual disability (4 variants)
- MYT1L-related disorder (1 variants)
- Neurodevelopmental disorder (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MYT1L gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 53 | 18 | 74 | |||
missense | 19 | 106 | 15 | 147 | ||
nonsense | 16 | 19 | ||||
start loss | 2 | |||||
frameshift | 13 | 21 | ||||
inframe indel | 12 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 2 | 7 | 5 | 14 | ||
non coding | 37 | 77 | 118 | |||
Total | 35 | 30 | 123 | 107 | 101 |
Variants in MYT1L
This is a list of pathogenic ClinVar variants found in the MYT1L region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-1791881-C-T | Uncertain significance (Jul 08, 2022) | |||
2-1791884-T-C | Inborn genetic diseases | Uncertain significance (Sep 29, 2023) | ||
2-1791896-TTA-T | Uncertain significance (Jan 21, 2022) | |||
2-1791899-T-C | Intellectual disability, autosomal dominant 39 | Uncertain significance (Jul 14, 2020) | ||
2-1791952-T-C | Uncertain significance (Jan 19, 2022) | |||
2-1791957-T-G | Inborn genetic diseases | Likely benign (Mar 30, 2024) | ||
2-1792001-T-C | Inborn genetic diseases | Uncertain significance (Feb 28, 2023) | ||
2-1792005-A-T | Inborn genetic diseases | Uncertain significance (Mar 30, 2024) | ||
2-1792276-C-T | Likely benign (Feb 15, 2020) | |||
2-1792348-G-T | Uncertain significance (Sep 14, 2021) | |||
2-1792367-C-T | Uncertain significance (Aug 01, 2023) | |||
2-1792383-C-G | Uncertain significance (Nov 13, 2019) | |||
2-1792454-A-G | Inborn genetic diseases | Uncertain significance (Sep 22, 2023) | ||
2-1792456-C-T | Likely benign (Apr 01, 2022) | |||
2-1792473-C-T | MYT1L-related disorder | Likely benign (Jun 12, 2019) | ||
2-1792691-T-C | Likely benign (Jul 21, 2019) | |||
2-1792707-T-C | Likely benign (Apr 09, 2019) | |||
2-1792732-T-G | Benign (Aug 10, 2018) | |||
2-1801553-A-G | Likely benign (Oct 28, 2019) | |||
2-1801657-C-T | Benign (Jul 11, 2020) | |||
2-1801658-G-A | Benign (Aug 10, 2018) | |||
2-1801717-A-G | Benign (Aug 10, 2018) | |||
2-1801726-C-T | MYT1L-related disorder | Uncertain significance (Sep 29, 2022) | ||
2-1801755-T-G | MYT1L-related disorder | Uncertain significance (Mar 13, 2024) | ||
2-1801758-T-G | Uncertain significance (Jan 13, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MYT1L | protein_coding | protein_coding | ENST00000428368 | 20 | 542148 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 1.36e-8 | 124643 | 0 | 2 | 124645 | 0.00000802 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.77 | 365 | 727 | 0.502 | 0.0000456 | 7928 |
Missense in Polyphen | 91 | 308 | 0.29545 | 3271 | ||
Synonymous | 2.25 | 254 | 304 | 0.836 | 0.0000229 | 2078 |
Loss of Function | 6.71 | 1 | 54.4 | 0.0184 | 0.00000270 | 674 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000889 | 0.00000885 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000328 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transcription factor that plays a key role in neuronal differentiation by specifically repressing expression of non- neuronal genes during neuron differentiation. In contrast to other transcription repressors that inhibit specific lineages, mediates repression of multiple differentiation programs. Also represses expression of negative regulators of neurogenesis, such as members of the Notch signaling pathway, including HES1. The combination of three transcription factors, ASCL1, POU3F2/BRN2 and MYT1L, is sufficient to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells in vitro. Directly binds the 5'-AAGTT- 3' core motif present on the promoter of target genes and represses transcription by recruiting a multiprotein complex containing SIN3B. The 5'-AAGTT-3' core motif is absent from the promoter of neural genes. {ECO:0000250|UniProtKB:P97500}.;
- Disease
- DISEASE: Mental retardation, autosomal dominant 39 (MRD39) [MIM:616521]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD39 patients show delayed psychomotor development and autistic features. {ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:23160955}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.116
Intolerance Scores
- loftool
- rvis_EVS
- -1.51
- rvis_percentile_EVS
- 3.54
Haploinsufficiency Scores
- pHI
- 0.307
- hipred
- Y
- hipred_score
- 0.755
- ghis
- 0.628
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.336
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Myt1l
- Phenotype
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;regulation of transcription by RNA polymerase II;nervous system development;neuron differentiation;positive regulation of transcription by RNA polymerase II;neuron fate commitment;neuron fate specification;neuron development
- Cellular component
- nucleus;chromosome
- Molecular function
- RNA polymerase II regulatory region sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;zinc ion binding